Larynx Cancer disease: Malacards - Research Articles, Drugs, Genes, Clinical Trials

MCID: LRY044 MIFTS: 60	Larynx Cancer Categories: Cancer diseases, Oral diseases, Rare diseases, Respiratory diseases
Genes Variations Tissues Related diseases Publications Pathways Drugs Expand all tables

Sources

Aliases & Classifications for Larynx Cancer

MalaCards integrated aliases for Larynx Cancer:

Name: Larynx Cancer ¹² ¹⁵

Laryngeal Carcinoma ¹² ⁷⁷ ⁵⁴ ⁵⁶ ¹⁵

Laryngeal Cancer ⁵⁴ ³⁸ ⁵⁶

Carcinoma of Larynx ¹² ⁷⁴

Laryngeal Neoplasm ¹⁷ ⁷⁴

Malignant Neoplasm of Larynx ⁷⁴

Laryngeal Neoplasms ⁴⁵

Cancer, Laryngeal ⁴¹

Cancer of Larynx ¹²

Classifications:

MalaCards categories:
Global: Rare diseases Cancer diseases
Anatomical: Respiratory diseases Oral diseases

See all MalaCards categories (disease lists)

ICD10: ³⁴

Neoplasms

Malignant neoplasms of respiratory and intrathoracic organs

Malignant neoplasm of larynx

Malignant neoplasm: Larynx, unspecified

External Ids:

Disease Ontology ¹² DOID:2596 DOID:2600

KEGG ³⁸ H00055

ICD9CM ³⁶ 161 161.9

MeSH ⁴⁵ D007822

NCIt ⁵¹ C4855 C7484

SNOMED-CT ⁶⁹ 93859007

ICD10 ³⁴ C32 C32.9

EFO ¹⁷ EFO_0003817

UMLS ⁷⁴ C0007107 C0023055 C0595989

Sources

Summaries for Larynx Cancer

Disease Ontology : ¹² A larynx cancer that has material basis in epithelial cells.

MalaCards based summary : Larynx Cancer, also known as laryngeal carcinoma, is related to laryngeal squamous cell carcinoma and verrucous carcinoma. An important gene associated with Larynx Cancer is MIR21 (MicroRNA 21), and among its related pathways/superpathways are Endometrial cancer and Drug metabolism - cytochrome P450. The drugs Magnesium Sulfate and Bupropion have been mentioned in the context of this disorder. Affiliated tissues include lung, breast and skin, and related phenotypes are Reduced mammosphere formation and Decreased focal adhesion (FA) area, decreased FA length, decreased FA mean intensity, increased number of small and round FAs, increased FA abundance

Wikipedia : ⁷⁷ Laryngeal cancer are mostly squamous cell carcinomas, reflecting their origin from the skin of the... more...

Sources

Related Diseases for Larynx Cancer

Diseases in the Larynx Cancer family:

Larynx Carcinoma in Situ

Diseases related to Larynx Cancer via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 244)

#	Related Disease	Score	Top Affiliating Genes
1	laryngeal squamous cell carcinoma	31.0	CCND1 CDKN2A EGFR GSTM3 GSTT1 MIR21
2	verrucous carcinoma	30.3	CCND1 CDKN2A TP53
3	asbestosis	30.1	GSTM1 GSTP1 GSTT1
4	in situ carcinoma	30.1	CDKN2A EGFR TP53
5	small cell carcinoma	29.9	CDKN2A EGFR PTEN TP53
6	inverted papilloma	29.9	CCND1 CDKN2A TP53
7	malignant peritoneal mesothelioma	29.9	CDKN2A EGFR
8	papilloma	29.8	CCND1 CDKN2A PTEN TP53
9	basaloid squamous cell carcinoma	29.7	CDKN2A EGFR TP53
10	adenoid cystic carcinoma	29.7	CCND1 PTEN SERPINB5 TP53
11	recurrent respiratory papillomatosis	29.7	EGFR TP53
12	oropharynx cancer	29.5	CCND1 CDKN2A EGFR TP53
13	lynch syndrome	29.3	CCND1 CDKN2A EGFR GSTM1 TP53
14	adenocarcinoma	29.3	CCND1 CDKN2A EGFR PTEN TP53
15	squamous cell carcinoma	28.8	CCND1 CD44 CDKN2A EGFR GSTP1 NME1
16	thyroid cancer	28.5	CCND1 EGFR GSTT1 PTEN SERPINB5 TERT
17	nasopharyngeal carcinoma	28.5	CCND1 CDKN2A EGFR GSTM1 NME1 TERT
18	pancreatic cancer	28.4	CCND1 CD44 CDKN2A DLEU2 EGFR MIR21
19	squamous cell carcinoma, head and neck	28.2	CCND1 CD44 CDKN2A EGFR FAM3D-AS1 GSTM1
20	esophageal cancer	28.0	CCND1 CD44 CDKN2A EGFR GSTM1 GSTP1
21	cervical cancer	28.0	CCND1 CD44 CDKN2A GSTM1 GSTP1 GSTT1
22	ovarian cancer	27.8	CCND1 CD44 EGFR GSTP1 MIR21 NME1
23	lung cancer	27.7	CCND1 CD44 CDKN2A EGFR GSTM1 GSTP1
24	breast cancer	27.5	CCND1 CD44 CTSD EGFR GSTP1 MIR21
25	laryngeal cancer, childhood	12.1
26	supraglottic laryngeal cancer	11.5
27	laryngeal mucoepidermoid carcinoma	11.2
28	laryngeal adenoid cystic carcinoma	11.2
29	laryngeal small cell carcinoma	11.2
30	larynx sarcoma	11.1
31	hearing loss, noise-induced	10.5	GSTM1 GSTT1
32	drug-induced hepatitis	10.4	GSTM1 GSTT1 NAT2
33	sister chromatid exchange, frequency of	10.4	GSTM1 GSTT1 XRCC1
34	diffuse gastric cancer	10.4	GSTM1 GSTP1 GSTT1
35	breast papillomatosis	10.4	CCND1 CDKN2A
36	senile cataract	10.4	GSTM1 GSTT1 XRCC1
37	tonsil squamous cell carcinoma	10.3	CCND1 CDKN2A
38	bladder squamous cell carcinoma	10.3	CDKN2A TP53
39	gastric adenosquamous carcinoma	10.3	CD44 CDKN2A TP53
40	keratinizing squamous cell carcinoma	10.3	CDKN2A TP53
41	xeroderma pigmentosum, complementation group d	10.3	GSTM1 GSTP1 GSTT1 XRCC1
42	ovarian clear cell carcinoma	10.3	CD44 PTEN TP53
43	skin carcinoma in situ	10.2	CCND1 CDKN2A
44	spitz nevus	10.2	CDKN2A TP53
45	sporadic breast cancer	10.2	PTEN TP53 XRCC1
46	acute lymphocytic leukemia	10.2	CDKN2A GSTM1 GSTT1 TP53
47	synchronous bilateral breast carcinoma	10.2	CCND1 PTEN TP53
48	basal cell carcinoma	10.2	GSTM1 GSTM3 GSTT1 TP53
49	skin melanoma	10.2	CDKN2A NME1 TP53
50	brain ependymoma	10.2	EGFR TP53

Comorbidity relations with Larynx Cancer via Phenotypic Disease Network (PDN):

Bronchitis	Deficiency Anemia
Pharynx Cancer	Protein-Energy Malnutrition
Respiratory Failure	Supraglottis Cancer
Swallowing Disorders

Graphical network of the top 20 diseases related to Larynx Cancer:

Sources

Symptoms & Phenotypes for Larynx Cancer

GenomeRNAi Phenotypes related to Larynx Cancer according to GeneCards Suite gene sharing:

²⁷

#	Description	GenomeRNAi Source Accession	Score	Top Affiliating Genes
1	Reduced mammosphere formation	GR00396-S	9.56	CCND1 CD44 EGFR GSTM1 GSTM3 NME1
2	Decreased focal adhesion (FA) area, decreased FA length, decreased FA mean intensity, increased number of small and round FAs, increased FA abundance	GR00210-A	9.55	CD44 CTSD EGFR GSTM1 PTEN
3	Synthetic lethal with MLN4924 (a NAE inhibitor)	GR00250-A-1	9.44	CDKN2A PTEN SERPINB5 TERT TP53 XRCC1
4	Synthetic lethal with MLN4924 (a NAE inhibitor)	GR00250-A-2	9.44	CCND1 CDKN2A PTEN SERPINB5 TERT TP53

MGI Mouse Phenotypes related to Larynx Cancer:

⁴⁷ (show all 11)

#	Description	MGI Source Accession	Score	Top Affiliating Genes
1	growth/size/body region	MP:0005378	10.23	CCND1 CD44 CDKN2A CTSD EGFR ENG
2	digestive/alimentary	MP:0005381	10.15	CCND1 CD44 CDKN2A CTSD EGFR ENG
3	mortality/aging	MP:0010768	10.15	CCND1 CD44 CDKN2A CTSD EGFR ENG
4	endocrine/exocrine gland	MP:0005379	10.13	CCND1 CD44 CDKN2A CTSD EGFR NME1
5	hematopoietic system	MP:0005397	10.13	CCND1 CD44 CDKN2A CTSD EGFR ENG
6	integument	MP:0010771	10.06	CCND1 CD44 CDKN2A CTSD EGFR ENG
7	nervous system	MP:0003631	10	CCND1 CD44 CDKN2A CTSD EGFR ENG
8	neoplasm	MP:0002006	9.97	CCND1 CD44 CDKN2A EGFR NME1 PTEN
9	normal	MP:0002873	9.81	CCND1 CD44 EGFR ENG PTEN SERPINB5
10	pigmentation	MP:0001186	9.35	CD44 CDKN2A EGFR PTEN TP53
11	respiratory system	MP:0005388	9.23	CCND1 CD44 CDKN2A EGFR ENG PTEN

Sources

Drugs & Therapeutics for Larynx Cancer

Drugs for Larynx Cancer (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 332)

Name

Status

Phase

Clinical Trials

Cas Number

PubChem Id

Magnesium Sulfate

Approved, Investigational, Vet_approved

Phase 4

7487-88-9

24083

Bupropion

Approved

Phase 4,Phase 2

34841-39-9, 34911-55-2

444

Dopamine

Approved

Phase 4,Phase 2

62-31-7, 51-61-6

681

Nicotine

Approved

Phase 4,Not Applicable

54-11-5

89594 942

Aspirin

Approved, Vet_approved

Phase 4,Phase 2

50-78-2

2244

Calcium

Approved, Nutraceutical

Phase 4,Phase 3,Phase 2

7440-70-2

271

Pharmaceutical Solutions

Phase 4,Phase 1,Early Phase 1,Not Applicable

Analgesics

Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable

Central Nervous System Depressants

Phase 4,Phase 3,Not Applicable

Anesthetics

Phase 4,Phase 3,Not Applicable

Peripheral Nervous System Agents

Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable

Liver Extracts

Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1

Neurotransmitter Agents

Phase 4,Phase 3,Phase 2,Not Applicable

Cytochrome P-450 Enzyme Inhibitors

Phase 4,Phase 2,Phase 3

Autonomic Agents

Phase 4,Phase 3,Phase 2,Not Applicable

Anti-Inflammatory Agents, Non-Steroidal

Phase 4,Phase 1,Phase 2

Cyclooxygenase Inhibitors

Phase 4,Phase 1,Phase 2

Analgesics, Non-Narcotic

Phase 4,Phase 1,Phase 2,Not Applicable

Antirheumatic Agents

Phase 4,Phase 3,Phase 1,Phase 2,Early Phase 1

Anti-Inflammatory Agents

Phase 4,Phase 1,Phase 2

Tocolytic Agents

Phase 4

Anti-Arrhythmia Agents

Phase 4

Calcium, Dietary

Phase 4,Phase 3,Phase 2

calcium channel blockers

Phase 4

Hormones

Phase 4,Phase 2,Phase 3,Phase 1

Anticonvulsants

Phase 4

Dopamine Uptake Inhibitors

Phase 4,Phase 2

Antidepressive Agents

Phase 4,Phase 3,Phase 2,Not Applicable

Neurotransmitter Uptake Inhibitors

Phase 4,Phase 2

Psychotropic Drugs

Phase 4,Phase 3,Phase 2,Not Applicable

Dopamine Agents

Phase 4,Phase 2

Cytochrome P-450 CYP2D6 Inhibitors

Phase 4,Phase 2

Antidepressive Agents, Second-Generation

Phase 4,Phase 2

Central Nervous System Stimulants

Phase 4,Phase 3,Not Applicable

Nicotinic Agonists

Phase 4,Not Applicable

Cholinergic Agents

Phase 4,Phase 2,Phase 3,Not Applicable

Antipyretics

Phase 4,Phase 2

Fibrinolytic Agents

Phase 4,Phase 2

Omega 3 Fatty Acid

Phase 4,Phase 2

Platelet Aggregation Inhibitors

Phase 4,Phase 2

Tegafur

Approved, Investigational

Phase 3

17902-23-7

5386

Cisplatin

Approved

Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable

15663-27-1

2767 441203 84093

Epirubicin

Approved

Phase 3,Phase 2,Phase 1

56420-45-2

41867

Epinephrine

Approved, Vet_approved

Phase 3,Phase 2

51-43-4

5816

Racepinephrine

Approved

Phase 3,Phase 2

329-65-7

838

Fluorouracil

Approved

Phase 3,Phase 2,Phase 1

51-21-8

3385

Docetaxel

Approved, Investigational

Phase 3,Phase 2,Phase 1

114977-28-5

148124

Ethanol

Approved

Phase 3

64-17-5

702

Carboplatin

Approved

Phase 3,Phase 2,Phase 1

41575-94-4

10339178 38904 498142

Hydroxyurea

Approved

Phase 3,Phase 2,Phase 1

127-07-1

3657

Interventional clinical trials:

(show top 50) (show all 421)

#	Name	Status	NCT ID	Phase	Drugs
1	Effect of Magnesium Sulphate Infusion on Lung Mechanics and Oxygenation in COPD Patients Undergoing Total Laryngeal	Completed	NCT03461328	Phase 4	Magnesium Sulphate
2	Health Education Counseling With or Without Bupropion in Helping African Americans Stop Smoking	Completed	NCT00666978	Phase 4	bupropion hydrochloride
3	Counseling and Nicotine Replacement Therapy in Helping Adult Smokers Quit Smoking	Completed	NCT00365508	Phase 4	nicotine lozenge;nicotine patch
4	ASCEND: A Study of Cardiovascular Events iN Diabetes	Active, not recruiting	NCT00135226	Phase 4	Aspirin;Omega-3 Ethyl Esters;Placebo Aspirin;Placebo Omega-3 Ethyl Esters
5	Radiotherapy Dose Escalation in Locally Advanced Squamous Cell Carcinoma of the Larynx or Hypopharynx	Withdrawn	NCT03388931	Phase 4
6	the Comparison of Voice Quality in Early Laryngeal Cancer Between Surgery and Radiotherapy	Unknown status	NCT00497588	Phase 3
7	Evaluation of 3DCRT Versus IGRT and Analysis of Early Response in Head and Neck Cancer.	Unknown status	NCT01124409	Phase 3
8	PET/CT Scan-Guided Watchful Waiting or Neck Dissection of Locally Advanced Lymph Node Metastases in Treating Patients Undergoing Chemotherapy and Radiation Therapy for Primary Head And Neck Cancer	Unknown status	NCT00720070	Phase 3
9	S-1 or Tegafur-Uracil in Treating Patients With Previously Treated Stage III or Stage IV Head and Neck Cancer	Unknown status	NCT00336947	Phase 3	tegafur-gimeracil-oteracil potassium;tegafur-uracil
10	Chemotherapy and Radiation Therapy With or Without Surgery in Treating Patients With Head and Neck Cancer	Unknown status	NCT00047008	Phase 3	cisplatin
11	Cisplatin Plus Epinephrine in Treating Patients With Recurrent or Refractory Head and Neck Cancer	Unknown status	NCT00002659	Phase 3	cisplatin-e therapeutic implant
12	Radiation Therapy With or Without Chemotherapy in Treating Patients With Advanced Cancer of the Larynx	Completed	NCT00002496	Phase 3	chemotherapy;cisplatin;fluorouracil
13	Randomized Trial of ARCON in Larynx Cancer	Completed	NCT00147732	Phase 3
14	Induction CT by Cisplatin, 5FU With or Without Docetaxel in Patients With T3 and T4 Larynx and Hypopharynx Carcinoma	Completed	NCT00169182	Phase 3	DOCETAXEL;Cisplatin;5-Fluoro-3-Pyridinecarboxylic Acid
15	Combination Chemotherapy Plus Radiation Therapy To Preserve the Larynx in Patients With Cancer of the Hypopharynx or Larynx	Completed	NCT00002839	Phase 3	cisplatin;fluorouracil
16	Comparison of 2 Cefazolin Prophylactic Protocol in Laryngectomy Patients	Completed	NCT00467948	Phase 3	cefazolin
17	Randomized Trial to Assess the Impact of a Screening Program on Upper Aerodigestive Tract Cancer Mortality in a High Risk Population	Completed	NCT00359645	Phase 3
18	Very Intense Radiotherapy-Chemotherapy Regimen in Advanced HNSCC	Completed	NCT00162708	Phase 2, Phase 3	CDDP, 5 Fu
19	Accelerated Radiotherapy and Concomitant Chemo-radiotherapy in HNSCC	Completed	NCT00158652	Phase 3	5FU, Paraplatin
20	Docetaxel Based Chemotherapy Plus or Minus Induction Chemotherapy to Decrease Events in Head and Neck Cancer (DeCIDE)	Completed	NCT00117572	Phase 3	docetaxel;cisplatin;hydroxyurea;fluorouracil
21	Acupuncture-Like Transcutaneous Electrical Nerve Stimulation (ALTENS) or Pilocarpine in Treating Early Dry Mouth in Patients Undergoing Radiation Therapy for Head and Neck Cancer	Completed	NCT00656513	Phase 2, Phase 3	Pilocarpine
22	Sargramostim in Decreasing Mucositis in Patients Receiving Radiation Therapy for Head and Neck Cancer	Completed	NCT00008398	Phase 3
23	Radiation Therapy in Treating Patients With Stage II Cancer of the Vocal Cord	Completed	NCT00002727	Phase 3
24	Doxepin Hydrochloride in Treating Oral Mucositis Pain in Patients With Head and Neck Cancer Undergoing Radiation Therapy With or Without Chemotherapy	Completed	NCT01156142	Phase 3	doxepin hydrochloride
25	Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain	Completed	NCT00538850	Phase 3	Fentanyl sublingual spray;Placebo
26	Acupuncture or Standard Therapy in Treating Pain and Dysfunction in Patients Who Have Undergone Neck Surgery for Head and Neck Cancer	Completed	NCT00090337	Phase 3
27	Fluconazole in Preventing Mucositis in Patients Undergoing Radiation Therapy for Head and Neck Cancer	Completed	NCT00002533	Phase 2, Phase 3	fluconazole
28	Study of Nutrition Regimens in Treating Patients With Cancer of the Upper Aerodigestive Tract	Completed	NCT00765440	Phase 3
29	Cevimeline in Treating Patients With Dry Mouth Caused by Radiation Therapy for Head and Neck Cancer	Completed	NCT00017511	Phase 3	cevimeline hydrochloride
30	Radiation Therapy and Cisplatin or Panitumumab in Treating Patients With Locally Advanced Stage III or Stage IV Head and Neck Cancer	Completed	NCT00820248	Phase 3	cisplatin
31	Megestrol to Limit Weight Loss and Improve Quality of Life in Treating Patients With Head and Neck Cancer	Completed	NCT00006799	Phase 3	megestrol acetate
32	Radiation Therapy With or Without Chemotherapy in Treating Patients With Advanced Head and Neck Cancer	Completed	NCT00002476	Phase 3	fluorouracil;leucovorin calcium;methotrexate;vincristine sulfate
33	Radiation Therapy and Chemotherapy in Treating Patients With Head and Neck Cancer	Completed	NCT00002507	Phase 3	mitomycin C;porfiromycin
34	Oral Mucositis in Patients Receiving Radiation Therapy for Cancer of the Mouth, Pharynx, or Larynx	Completed	NCT00004234	Phase 3
35	Radiation Therapy in Treating Patients With Head and Neck Cancer	Completed	NCT00021125	Phase 3
36	Radiation Therapy With or Without Epoetin Alfa in Treating Anemic Patients With Head and Neck Cancer	Completed	NCT00004917	Phase 3	cisplatin
37	Combination Chemotherapy in Treating Patients With Advanced Head and Neck Cancer	Completed	NCT00002888	Phase 3	cisplatin;fluorouracil;paclitaxel
38	Cisplatin With or Without Monoclonal Antibody Therapy in Treating Patients With Metastatic or Recurrent Head and Neck Cancer	Completed	NCT00003809	Phase 3	cisplatin
39	Radiation Therapy With or Without Chemotherapy in Treating Patients With Head and Neck Cancer That Has Been Removed During Surgery	Completed	NCT00002670	Phase 3	chemotherapy;cisplatin
40	Combination Chemotherapy and Radiation in Treating Patients With Stage III or IV Head and Neck Cancer (Paradigm Trial)	Completed	NCT00095875	Phase 3	carboplatin;cisplatin;docetaxel;fluorouracil
41	Radiation Therapy Cisplatin With or Without Fluorouracil Patients With Stage III or Stage IV Head and Neck Cancer	Completed	NCT00608205	Phase 3	cisplatin;fluorouracil
42	Methotrexate Compared With Paclitaxel in Treating Patients With Advanced Head and Neck Cancer	Completed	NCT00003592	Phase 3	methotrexate;paclitaxel
43	Fractionated Radiation Therapy in Treating Advanced Squamous Cell Carcinoma of the Head and Neck	Completed	NCT00771641	Phase 3
44	Isotretinoin, Interferon Alfa, and Vitamin E in Treating Patients With Stage III or Stage IV Head and Neck Cancer	Completed	NCT00054561	Phase 3	isotretinoin
45	Radiation Therapy Plus Porfiromycin in Treating Patients With Stage III or Stage IV Head and Neck Cancer	Completed	NCT00003328	Phase 3	porfiromycin
46	Radiation Therapy With or Without Cisplatin in Treating Patients With Advanced Head and Neck Cancer	Completed	NCT00002654	Phase 3	chemotherapy;cisplatin
47	High-Dose Radiation Therapy With or Without Chemotherapy in Treating Patients With Head and Neck Cancer	Completed	NCT00002555	Phase 3	cisplatin
48	Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Advanced Head and Neck Cancer	Completed	NCT00003888	Phase 3	cisplatin;docetaxel;fluorouracil
49	Biafine Cream to Reduce Side Effects of Radiation Therapy in Patients Receiving Treatment for Advanced Head and Neck Cancer	Completed	NCT00006481	Phase 3	Biafine cream
50	Surgery and Radiation Therapy Compared With Chemotherapy and Radiation Therapy in Treating Patients With Stage III or Stage IV Head and Neck Cancer That Can Be Removed During Surgery	Completed	NCT00003576	Phase 3	cisplatin;fluorouracil

Search NIH Clinical Center for Larynx Cancer

Cochrane evidence based reviews: laryngeal neoplasms

Sources

Genetic Tests for Larynx Cancer

Sources

Anatomical Context for Larynx Cancer

MalaCards organs/tissues related to Larynx Cancer:

⁴²

Lung, Breast, Skin, Lymph Node, Brain, Liver, Thyroid

Sources

Publications for Larynx Cancer

Articles related to Larynx Cancer:

(show top 50) (show all 1252)

#	Title	Authors	Year
1	Detection of laryngeal carcinoma in the U.S. elderly population with gastroesophageal reflux disease. ( 30681216 )	Riley CA...McCoul ED	2019
2	Increased risk of larynx cancer in patients with gastroesophageal reflux disease from a national sample cohort. ( 30884136 )	Kim SY...Choi HG	2019
3	Does Socioeconomic Status Affect Stage at Presentation for Larynx Cancer in Canada's Universal Health Care System? ( 30200820 )	Khalil D...Johnson-Obaseki S	2019
4	Association of Hospital Volume With Laryngectomy Outcomes in Patients With Larynx Cancer. ( 30476965 )	Gourin CG...Austin JM	2019
5	Improving decision making in larynx cancer by developing a decision aid: A mixed methods approach. ( 30663068 )	Petersen JF...van den Brekel MWM	2019
6	Volumetric modulated arc therapy with robust optimization for larynx cancer. ( 30824150 )	Miura H...Nagata Y	2019
7	Phase 1 Fractional Dose-Escalation Study of Equipotent Stereotactic Radiation Therapy Regimens for Early-Stage Glottic Larynx Cancer. ( 30880269 )	Sher DJ...Sumer BD	2019
8	Failed larynx preservation and survival in patients with advanced larynx cancer. ( 31036417 )	Nocon CC...Bhayani MK	2019
9	Nuclear expression of onco-suppressors nm23-H1 and maspin are associated with lower recurrence rate in laryngeal carcinoma. ( 30683471 )	Marioni G...Blandamura S	2019
10	Tumor budding in laryngeal carcinoma. ( 30706852 )	Ekmekci S...Gumussoy M	2019
11	Presentation of second primary cancers in young laryngeal carcinoma patients. ( 30712430 )	Sil?n S...M?kitie A	2019
12	Radiotherapy in advanced glottic laryngeal carcinoma in a patient with Wegener's granulomatosis: how much radiation dose is needed? ( 30774363 )	Lazzari G...Silvano G	2019
13	Clinical Utility of Pretreatment and 3-Month 18F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography Standardized Uptake Value in Predicting and Assessing Recurrence in T3-T4 Laryngeal Carcinoma Treated With Definitive Radiation. ( 30808209 )	Mayo Z...Anderson C	2019
14	β-Arrestin-1 expression and epithelial-to-mesenchymal transition in laryngeal carcinoma. ( 30854928 )	Marioni G...Fassina A	2019
15	The prognostic value of preoperative derived neutrophil-to-lymphocyte ratio in patients undergoing total laryngectomy with laryngeal carcinoma. ( 30882257 )	Song S...Zhou H	2019
16	Aspernolide A Inhibits the Proliferation of Human Laryngeal Carcinoma Cells through the Mitochondrial Apoptotic and STAT3 Signaling Pathways. ( 30893785 )	Liu C...Yang X	2019
17	Pepsin promotes IL-8 signaling-induced epithelial-mesenchymal transition in laryngeal carcinoma. ( 30936780 )	Tan JJ...Li XP	2019
18	Clinical significance of miRNA-195 expression in patients with laryngeal carcinoma. ( 30941987 )	Ding D...Qi Z	2019
19	The prognostic value of sex hormone receptors expression in laryngeal carcinoma. ( 30947969 )	Atef A...Kabel AM	2019
20	Second primary malignancies in laryngeal carcinoma patients treated with definitive radiotherapy. ( 30950440 )	Ozdemir Y...Topkan E	2019
21	Second primary malignancies in patients with radiotherapy-treated laryngeal carcinoma - A commentary. ( 30950441 )	Sharma D...Goel V	2019
22	DGCR5 promotes cancer stem cell-like properties of radioresistant laryngeal carcinoma cells by sponging miR-506 via Wnt pathway. ( 30980388 )	Tang T...Shan G	2019
23	Value of patient-reported symptoms in the follow up of patients potentially cured of laryngeal carcinoma. ( 31006407 )	Brandstorp-Boesen J...Boysen M	2019
24	Association of SNPs in the OBFC1 gene and laryngeal carcinoma in Chinese Han male population. ( 31016429 )	Han P...Shao Y	2019
25	Oncological results of salvage laryngectomy in patients with laryngeal carcinoma. ( 31030804 )	Le?n X...Quer M	2019
26	Laser transoral microsurgery in treatment of early laryngeal carcinoma. ( 31053965 )	Djukic V...Satueva DB	2019
27	The rising rate of nonsmokers among laryngeal carcinoma patients: Are we facing a new disease? ( 31090946 )	Shoffel-Havakuk H...Lahav Y	2019
28	Comparative p16IKN4A Expression in Laryngeal Carcinoma and Cervical Cancer Precursors: A Real-time Grid-based Immunocytochemistry Analysis. ( 30275203 )	Tsiambas E...Ragos V	2018
29	Laryngeal Tuberculosis Mimicking Laryngeal Carcinoma on 18F-FDG PET/CT Imaging. ( 29889030 )	Cengiz A...Y?rekli Y	2018
30	Treatment, short-term outcomes, and costs associated with larynx cancer care in commercially insured patients. ( 28685830 )	Day AT...Gourin CG	2018
31	Development and external validation of a risk-prediction model to predict 5-year overall survival in advanced larynx cancer. ( 29114897 )	Petersen JF...van den Brekel MWM	2018
32	Characterizing an Ultra-High-Risk Subset of Patients With Hypopharynx and Larynx Cancer: The Power of Lymph Node Burden. ( 29192300 )	Orosco RK...Cohen EE	2018
33	Effect of rural and urban geography on larynx cancer incidence and survival. ( 29238975 )	Zuniga SA...Lango MN	2018
34	Salvage Surgery after Radiation Failure in T1/T2 Larynx Cancer: Outcomes following Total versus Conservation Surgery. ( 29292665 )	Cheraghlou S...Judson BL	2018
35	Quality of life in patients with larynx cancer in Latin America: Comparison between laryngectomy and organ preservation protocols. ( 29554402 )	Sanabria A...Alvarez A	2018
36	Three-dimensional imaging assessment of anatomic invasion and volumetric considerations for chemo/radiotherapy-based laryngeal preservation in T3 larynx cancer. ( 29598944 )	Kamal M...Rosenthal DI	2018
37	Impact of HPV Status on the Prognostic Potential of the AJCC Staging System for Larynx Cancer. ( 29611770 )	Davidson SM...Witek ME	2018
38	Epidemiological features of cancers of the oral cavity, oropharynx, hypopharynx and larynx cancer in Réunion Island. ( 29673737 )	Delagranda A...Rubin F	2018
39	Decision making in advanced larynx cancer: An evidenced based review. ( 30409301 )	Eskander A...Dziegielewski PT	2018
40	From VA Larynx to the future of chemoselection: Defining the role of induction chemotherapy in larynx cancer. ( 30409302 )	Spector ME...Birkeland AC	2018
41	Organ preservation for advanced larynx cancer: A review of chemotherapy and radiation combination strategies. ( 30409316 )	Bonomi MR...Blakaj D	2018
42	Comet assay is not useful to predict normal tissue response after radiochemotherapy in cervical and larynx cancer patients. ( 30786692 )	Adamczyk A...Mucha-Ma?ecka A	2018
43	Lemierre Syndrome as a Complication of Laryngeal Carcinoma. ( 29849275 )	Colbert C...Bull L	2018
44	Beclin1 enhances cisplatin-induced apoptosis via Bcl-2-modulated autophagy in laryngeal carcinoma cells Hep-2. ( 29322787 )	Yang M...Li SS	2018
45	Feasibility of Salvage Selective Neck Dissection after Primary Irradiation of Pharyngeal and Laryngeal Carcinoma. ( 29428959 )	Mat Lazim N...Tan IB	2018
46	NBS1 rs2735383 polymorphism is associated with an increased risk of laryngeal carcinoma. ( 29433451 )	Hu X...Nong Q	2018
47	Fasudil inhibits proliferation and migration of Hep-2 laryngeal carcinoma cells. ( 29503530 )	Zhang X...Wu N	2018
48	Variation in prognosis of early laryngeal carcinoma after different types of cordectomy with transoral laser microsurgery. ( 29504443 )	Ding S...Zhang Y	2018
49	TIMP-3 Increases the Chemosensitivity of Laryngeal Carcinoma to Cisplatin via Facilitating Mitochondria-Dependent Apoptosis. ( 29523219 )	Shen X...Wang J	2018
50	The value of whole-body contrast-enhanced 18F-FDG PET/CT imaging in the diagnosis and staging of patients with laryngeal carcinoma. ( 29533345 )	Tatar G...Yigit O	2018

Sources

Genes for Larynx Cancer

Genes related to Larynx Cancer (1 elite genes):

(show all 22)

- Elite gene

- Cancer Census gene in COSMIC

#	Symbol	Description	Category	Score	Evidence	PubmedIds
1	MIR21	MicroRNA 21	RNA Gene	350	Causal ⁴⁸	19546886
2	DLEU2	Deleted In Lymphocytic Leukemia 2	RNA Gene	150	Experimental evidence: Expression ⁴⁰
3	FAM3D-AS1	FAM3D Antisense RNA 1	RNA Gene	150	Experimental evidence: Regulation ⁴⁰	25904139
4	NME1	NME/NM23 Nucleoside Diphosphate Kinase 1	Protein Coding	33.21	DISEASES inferred ¹⁵ ¹⁵ Novoseek inferred ⁵⁶	12768677 12014221 11265374 (more) 12815897 9616278 9642340 18476632 11080791 11387948 12764847 8635091 11189167
5	GSTM1	Glutathione S-Transferase Mu 1	Protein Coding	32.51	DISEASES inferred ¹⁵ ¹⁵ Novoseek inferred ⁵⁶ GeneCards inferred via : Publications (show sections)	15127559 11097350 9456238 (more) 12359356 12748560 10067818 14594555 11477586
6	GSTM3	Glutathione S-Transferase Mu 3	Protein Coding	31.68	DISEASES inferred ¹⁵ ¹⁵ Novoseek inferred ⁵⁶ GeneCards inferred via : Publications (show sections)	10067818 12359356 10407823
7	TP53	Tumor Protein P53	Protein Coding	30.97	DISEASES inferred ¹⁵ ¹⁵ Novoseek inferred ⁵⁶	11699821 12600081 8386140 (more) 12815897 11205233 12881872 7654413 18800676 9687893 12768762 9193221 15835821 11189420 18330257 8762527 7781800 10073037 8780536 11265384 17207318 10875157 9874454 7788934 10499619 9097709 17352251 20108544 9563667 9197477 19160427 18476631 11829192 11400228 12768677 9197495 18559058 18519232 16075975 15067348 11200824 9583028 10323025 15039212 12536563 10852523 16891205 16809096 15831046 12175687 10810258 10337529 8616872 9445184 15467627 12656410 12541678 9267820 19072995 18509272 14551784 10953333 10419041 19724860 11520092 12761983
8	CCND1	Cyclin D1	Protein Coding	28.45	DISEASES inferred ¹⁵ ¹⁵ Novoseek inferred ⁵⁶	15354413 17139501 14551784 (more) 16881553 18329328 11189154 9738577 9816104 15467627 19160427 12669430 18268491 16270530 9545767 15509364 8616872 19724860 12649172
9	CDKN2A	Cyclin Dependent Kinase Inhibitor 2A	Protein Coding	28.22	DISEASES inferred ¹⁵ ¹⁵ GeneCards inferred via : Publications (show sections)
10	CTSD	Cathepsin D	Protein Coding	28.21	DISEASES inferred ¹⁵ ¹⁵ Novoseek inferred ⁵⁶	10850757 9135974 8962695 (more) 8608976 11080791 10652611 11299783 8443785 12528259 11012985
11	NAT2	N-Acetyltransferase 2	Protein Coding	27.63	DISEASES inferred ¹⁵ ¹⁵ Novoseek inferred ⁵⁶ GeneCards inferred via : Publications (show sections)	12015038 10208649
12	TERT	Telomerase Reverse Transcriptase	Protein Coding	27.57	DISEASES inferred ¹⁵ ¹⁵ Novoseek inferred ⁵⁶	17592663 19159530
13	GSTP1	Glutathione S-Transferase Pi 1	Protein Coding	26.68	DISEASES inferred ¹⁵ ¹⁵ Novoseek inferred ⁵⁶ GeneCards inferred via : Publications (show sections)	10067818 12359356
14	SERPINB5	Serpin Family B Member 5	Protein Coding	26.44	DISEASES inferred ¹⁵ ¹⁵ Novoseek inferred ⁵⁶	18439947 15842640 17214364 (more) 18236066
15	EGFR	Epidermal Growth Factor Receptor	Protein Coding	26.43	DISEASES inferred ¹⁵ ¹⁵ Novoseek inferred ⁵⁶	19427146 11721445 12541404 (more) 9639720 19148533 17190429 15338866 1516034 18172732 18329328 10932015 9271009 8291440 20052590 20512084 9197492 19789511 9197495 14666705 8616872
16	PTEN	Phosphatase And Tensin Homolog	Protein Coding	26.24	DISEASES inferred ¹⁵ ¹⁵ GeneCards inferred via : Publications (show sections)
16	PTEN::MIR21 ⁴⁸	MIR21 Macro RNA (hsa-miR-21) targets PTEN
17	ENG	Endoglin	Protein Coding	26.12	DISEASES inferred ¹⁵ ¹⁵ Novoseek inferred ⁵⁶	18383901 18330257
18	GSTT1	Glutathione S-Transferase Theta 1	Protein Coding	26.08	Novoseek inferred ⁵⁶ GeneCards inferred via : Publications (show sections)	8561822 11097350 9456238 (more) 12359356 10067818
19	CD44	CD44 Molecule (Indian Blood Group)	Protein Coding	25.9	DISEASES inferred ¹⁵ ¹⁵ GeneCards inferred via : Publications (show sections)
20	XRCC1	X-Ray Repair Cross Complementing 1	Protein Coding	25.83	DISEASES inferred ¹⁵ ¹⁵ Novoseek inferred ⁵⁶ GeneCards inferred via : Publications (show sections)	15608415
21	MMP2	Matrix Metallopeptidase 2	Protein Coding	25.55	DISEASES inferred ¹⁵ ¹⁵ Novoseek inferred ⁵⁶	17888194 18062285 18431027 (more) 10320094 17649730 11843925
22	MMP14	Matrix Metallopeptidase 14	Protein Coding	25.46	DISEASES inferred ¹⁵ ¹⁵ Novoseek inferred ⁵⁶	10491020 18552024 15563089 (more) 18080692 15506641 14729463

Sources

Variations for Larynx Cancer

Cosmic variations for Larynx Cancer:

⁹ (show top 50) (show all 322)

#	Cosmic Mut ID	Gene Symbol	COSMIC Disease Classification (Primary site, Site subtype, Primary histology, Histology subtype)	Mutation CDS	Mutation AA	GRCh38 Location
1	COSM6927812	ZFHX3	upper aerodigestive tract,larynx,carcinoma,squamous cell carcinoma	c.4946C>T	p.S1649F	16:72797736-72797736
2	COSM45571	TP53	upper aerodigestive tract,larynx,carcinoma,squamous cell carcinoma	c.593A>G	p.E198G	17:7674938-7674938
3	COSM10714	TP53	upper aerodigestive tract,larynx,carcinoma,squamous cell carcinoma	c.473G>T	p.R158L	17:7675139-7675139
4	COSM11066	TP53	upper aerodigestive tract,larynx,carcinoma,squamous cell carcinoma	c.578A>T	p.H193L	17:7674953-7674953
5	COSM11245	TP53	upper aerodigestive tract,larynx,carcinoma,squamous cell carcinoma	c.430C>T	p.Q144*	17:7675182-7675182
6	COSM10779	TP53	upper aerodigestive tract,larynx,carcinoma,squamous cell carcinoma	c.818G>T	p.R273L	17:7673802-7673802
7	COSM10905	TP53	upper aerodigestive tract,larynx,carcinoma,squamous cell carcinoma	c.451C>T	p.P151S	17:7675161-7675161
8	COSM43690	TP53	upper aerodigestive tract,larynx,carcinoma,squamous cell carcinoma	c.592G>A	p.E198K	17:7674939-7674939
9	COSM10888	TP53	upper aerodigestive tract,larynx,carcinoma,squamous cell carcinoma	c.378C>A	p.Y126*	17:7675234-7675234
10	COSM6549	TP53	upper aerodigestive tract,larynx,carcinoma,squamous cell carcinoma	c.743G>T	p.R248L	17:7674220-7674220
11	COSM10659	TP53	upper aerodigestive tract,larynx,carcinoma,squamous cell carcinoma	c.817C>T	p.R273C	17:7673803-7673803
12	COSM10893	TP53	upper aerodigestive tract,larynx,carcinoma,squamous cell carcinoma	c.824G>A	p.C275Y	17:7673796-7673796
13	COSM44475	TP53	upper aerodigestive tract,larynx,carcinoma,squamous cell carcinoma	c.871A>T	p.K291*	17:7673749-7673749
14	COSM10813	TP53	upper aerodigestive tract,larynx,carcinoma,squamous cell carcinoma	c.394A>G	p.K132E	17:7675218-7675218
15	COSM11462	TP53	upper aerodigestive tract,larynx,carcinoma,squamous cell carcinoma	c.388C>G	p.L130V	17:7675224-7675224
16	COSM6906	TP53	upper aerodigestive tract,larynx,carcinoma,squamous cell carcinoma	c.672+1G>A	p.?	17:7674858-7674858
17	COSM44219	TP53	upper aerodigestive tract,larynx,carcinoma,squamous cell carcinoma	c.405C>G	p.C135W	17:7675207-7675207
18	COSM44067	TP53	upper aerodigestive tract,larynx,carcinoma,squamous cell carcinoma	c.721T>A	p.S241T	17:7674242-7674242
19	COSM11305	TP53	upper aerodigestive tract,larynx,carcinoma,squamous cell carcinoma	c.809T>C	p.F270S	17:7673811-7673811
20	COSM11658	TP53	upper aerodigestive tract,larynx,carcinoma,squamous cell carcinoma	c.955A>T	p.K319*	17:7673573-7673573
21	COSM44071	TP53	upper aerodigestive tract,larynx,carcinoma,squamous cell carcinoma	c.955A>G	p.K319E	17:7673573-7673573
22	COSM44352	TP53	upper aerodigestive tract,larynx,carcinoma,squamous cell carcinoma	c.850A>C	p.T284P	17:7673770-7673770
23	COSM10889	TP53	upper aerodigestive tract,larynx,carcinoma,squamous cell carcinoma	c.536A>G	p.H179R	17:7675076-7675076
24	COSM10758	TP53	upper aerodigestive tract,larynx,carcinoma,squamous cell carcinoma	c.659A>G	p.Y220C	17:7674872-7674872
25	COSM10660	TP53	upper aerodigestive tract,larynx,carcinoma,squamous cell carcinoma	c.818G>A	p.R273H	17:7673802-7673802
26	COSM10742	TP53	upper aerodigestive tract,larynx,carcinoma,squamous cell carcinoma	c.578A>G	p.H193R	17:7674953-7674953
27	COSM10777	TP53	upper aerodigestive tract,larynx,carcinoma,squamous cell carcinoma	c.715A>G	p.N239D	17:7674248-7674248
28	COSM44456	TP53	upper aerodigestive tract,larynx,carcinoma,squamous cell carcinoma	c.668C>A	p.P223H	17:7674863-7674863
29	COSM43949	TP53	upper aerodigestive tract,larynx,carcinoma,squamous cell carcinoma	c.401T>G	p.F134C	17:7675211-7675211
30	COSM10645	TP53	upper aerodigestive tract,larynx,carcinoma,squamous cell carcinoma	c.527G>T	p.C176F	17:7675085-7675085
31	COSM43935	TP53	upper aerodigestive tract,larynx,carcinoma,squamous cell carcinoma	c.577C>A	p.H193N	17:7674954-7674954
32	COSM44103	TP53	upper aerodigestive tract,larynx,carcinoma,squamous cell carcinoma	c.737T>A	p.M246K	17:7674226-7674226
33	COSM10654	TP53	upper aerodigestive tract,larynx,carcinoma,squamous cell carcinoma	c.637C>T	p.R213*	17:7674894-7674894
34	COSM10648	TP53	upper aerodigestive tract,larynx,carcinoma,squamous cell carcinoma	c.524G>A	p.R175H	17:7675088-7675088
35	COSM44143	TP53	upper aerodigestive tract,larynx,carcinoma,squamous cell carcinoma	c.919+1G>A	p.?	17:7673700-7673700
36	COSM43826	TP53	upper aerodigestive tract,larynx,carcinoma,squamous cell carcinoma	c.706T>A	p.Y236N	17:7674257-7674257
37	COSM44278	TP53	upper aerodigestive tract,larynx,carcinoma,squamous cell carcinoma	c.791T>C	p.L264P	17:7673829-7673829
38	COSM98254	TP53	upper aerodigestive tract,larynx,carcinoma,squamous cell carcinoma	c.782+1G>A	p.?	17:7674180-7674180
39	COSM11374	TP53	upper aerodigestive tract,larynx,carcinoma,squamous cell carcinoma	c.752T>A	p.I251N	17:7674211-7674211
40	COSM44678	TP53	upper aerodigestive tract,larynx,carcinoma,squamous cell carcinoma	c.415A>T	p.K139*	17:7675197-7675197
41	COSM43947	TP53	upper aerodigestive tract,larynx,carcinoma,squamous cell carcinoma	c.614A>G	p.Y205C	17:7674917-7674917
42	COSM45544	TP53	upper aerodigestive tract,larynx,carcinoma,squamous cell carcinoma	c.947C>T	p.P316L	17:7673581-7673581
43	COSM11081	TP53	upper aerodigestive tract,larynx,carcinoma,squamous cell carcinoma	c.733G>T	p.G245C	17:7674230-7674230
44	COSM10743	TP53	upper aerodigestive tract,larynx,carcinoma,squamous cell carcinoma	c.848G>C	p.R283P	17:7673772-7673772
45	COSM43753	TP53	upper aerodigestive tract,larynx,carcinoma,squamous cell carcinoma	c.560-1G>A	p.?	17:7674972-7674972
46	COSM44225	TP53	upper aerodigestive tract,larynx,carcinoma,squamous cell carcinoma	c.859G>A	p.E287K	17:7673761-7673761
47	COSM43597	TP53	upper aerodigestive tract,larynx,carcinoma,squamous cell carcinoma	c.538G>T	p.E180*	17:7675074-7675074
48	COSM44808	TP53	upper aerodigestive tract,larynx,carcinoma,squamous cell carcinoma	c.503A>C	p.H168P	17:7675109-7675109
49	COSM11354	TP53	upper aerodigestive tract,larynx,carcinoma,squamous cell carcinoma	c.991C>T	p.Q331*	17:7673537-7673537
50	COSM10726	TP53	upper aerodigestive tract,larynx,carcinoma,squamous cell carcinoma	c.856G>A	p.E286K	17:7673764-7673764

Sources

Expression for Larynx Cancer

Search GEO for disease gene expression data for Larynx Cancer.

Sources

Pathways for Larynx Cancer

Pathways related to Larynx Cancer according to GeneCards Suite gene sharing:

(show all 35)

#	Super pathways	Score	Top Affiliating Genes
1	Endometrial cancer ³⁸ Show member pathways Acute myeloid leukemia ³⁸ Binding of TCF/LEF-CTNNB1 to target gene promoters ⁶⁷ Chronic myeloid leukemia ³⁸ Colorectal cancer ³⁸ Pancreatic cancer ³⁸ Prostate cancer ³⁸ Signal transduction PTEN pathway ²³ Thyroid cancer ³⁸	12.8	CCND1 CDKN2A EGFR GSTP1 PTEN TP53
2	Drug metabolism - cytochrome P450 ³⁸ Show member pathways Aflatoxin B1 metabolism ¹ Artemisinin and Derivatives Pathway, Pharmacokinetics ⁶² Arylamine metabolism ¹ Benzo[a]pyrene metabolism ²³ Benzodiazepine Pathway, Pharmacokinetics ⁶² Celecoxib Pathway, Pharmacokinetics ⁶² Chemical carcinogenesis ³⁸ Drug metabolism - other enzymes ³⁸ Fluvoxamine Pathway, Pharmacokinetics ⁶² Haloperidol Pathway, Pharmacokinetics ⁶² Ifosfamide Pathway, Pharmacokinetics ⁶² Metabolism of xenobiotics by cytochrome P450 ³⁸ Naproxen Pathway, Pharmacokinetics ⁶² Nicotine Metabolism ¹ Nicotine Pathway, Pharmacokinetics ⁶² Oxycodone Pathway, Pharmacokinetics ⁶² Retinol metabolism ²³ Retinol metabolism ³⁸ Sertraline Pathway, Pharmacokinetics ⁶² Voriconazole Pathway, Pharmacokinetics ⁶²	12.75	GSTM1 GSTM3 GSTP1 GSTT1 NAT2 NME1
3	Glioma ³⁸ Show member pathways Endocrine resistance ³⁸ Melanoma ³⁸ Non-small cell lung cancer ³⁸ Signaling Pathways in Glioblastoma ¹	12.63	CCND1 CDKN2A EGFR PTEN TP53
4	DNA Damage ⁴	12.44	CCND1 CDKN2A GSTP1 TP53 XRCC1
5	Pathways in cancer ³⁸	12.38	CCND1 CDKN2A EGFR GSTM1 GSTM3 GSTP1
6	MicroRNAs in cancer ³⁸	12.33	CCND1 CD44 CDKN2A EGFR MIR21 PTEN
7	Human T-cell leukemia virus 1 infection ³⁸	12.29	CCND1 CDKN2A TERT TP53
8	DNA Damage Response ¹ Show member pathways miRNA Regulation of DNA Damage Response ¹ p53 signaling pathway ³⁸	12.26	CCND1 CDKN2A PTEN SERPINB5 TP53
9	Glutathione metabolism ²³ ¹ ³⁸ Show member pathways 4-hydroxy-2-nonenal detoxification ¹ gamma-glutamyl cycle ¹ Glutathione conjugation ⁶⁷ glutathione redox reactions I ¹ Glutathione synthesis and recycling ⁶⁷ glutathione-mediated detoxification ¹	12.23	GSTM1 GSTM3 GSTP1 GSTT1
10	Proteoglycans in cancer ³⁸	12.18	CCND1 CD44 EGFR MIR21 TP53
11	MAPK Signaling: Mitogen Stimulation Pathway ⁶⁶ Show member pathways Akt Signaling Pathway ⁶⁶	12.14	CCND1 EGFR PTEN TP53
12	Cellular senescence (KEGG) ³⁸	12.1	CCND1 CDKN2A PTEN TP53
13	Integrated Breast Cancer Pathway ¹	12.08	CCND1 EGFR PTEN TP53
14	AKT Signaling Pathway ⁶⁸	12.07	CCND1 EGFR PTEN TP53
15	Gastric cancer ³⁸ Show member pathways Breast cancer ³⁸ Hepatocellular carcinoma ³⁸	11.99	CCND1 CDKN2A EGFR GSTM1 GSTM3 GSTP1
16	Fluid shear stress and atherosclerosis ³⁸	11.94	GSTM1 GSTM3 GSTP1 GSTT1 TP53
17	DNA Damage Response (only ATM dependent) ¹	11.92	CCND1 CDKN2A PTEN TP53
18	Direct p53 effectors ¹	11.89	CTSD EGFR PTEN SERPINB5 TP53
19	Senescence and Autophagy in Cancer ¹	11.85	CD44 CDKN2A PTEN TP53
20	Small cell lung cancer ³⁸	11.81	CCND1 PTEN TP53
21	Androgen receptor signaling pathway ¹	11.79	CCND1 EGFR PTEN
22	Glioblastoma Multiforme ⁶⁵	11.76	CCND1 CDKN2A EGFR PTEN TP53
23	Validated targets of C-MYC transcriptional activation ¹	11.73	NME1 TERT TP53
24	Acetaminophen Pathway (therapeutic doses), Pharmacokinetics ⁶² Show member pathways 2-Naphthylamine and 2-Nitronaphtalene metabolism ²³ Acetaminophen metabolism ²³ Acetaminophen Pathway (toxic doses), Pharmacokinetics ⁶²	11.72	GSTM1 GSTP1 GSTT1
25	Regulation of Telomerase ¹	11.63	CCND1 EGFR TERT
26	Central carbon metabolism in cancer ³⁸	11.62	EGFR PTEN TP53
27	Bladder cancer ¹ ³⁸	11.62	CCND1 CDKN2A EGFR TP53
28	Copper homeostasis ¹	11.52	CCND1 PTEN TP53
29	Platinum drug resistance ³⁸	11.5	CDKN2A GSTM1 GSTM3 GSTP1 GSTT1 TP53
30	Hepatitis C and Hepatocellular Carcinoma ¹	11.49	CCND1 CD44 TP53
31	Photodynamic therapy-induced AP-1 survival signaling. ¹	11.44	CCND1 CDKN2A EGFR TP53
32	Busulfan Pathway, Pharmacodynamics ⁶² Show member pathways Catalytic cycle of mammalian Flavin-containing MonoOxygenases (FMOs) ¹ FMO oxidises nucleophiles ⁶⁷	11.4	GSTM1 GSTP1 NAT2
33	Platinum Pathway, Pharmacokinetics/Pharmacodynamics ⁶²	11.17	GSTM1 GSTP1 GSTT1
34	Naphthalene metabolism ²³	11.07	GSTM1 GSTP1 GSTT1
35	Etoposide Pathway, Pharmacokinetics/Pharmacodynamics ⁶²	10.84	GSTP1 GSTT1

Sources

GO Terms for Larynx Cancer

Cellular components related to Larynx Cancer according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	PML body	GO:0016605	8.8	PTEN TERT TP53

Biological processes related to Larynx Cancer according to GeneCards Suite gene sharing:

(show all 23)

#	Name	GO ID	Score	Top Affiliating Genes
1	negative regulation of cell proliferation	GO:0008285	9.95	CDKN2A MIR21 NME1 PTEN TP53
2	positive regulation of gene expression	GO:0010628	9.91	CDKN2A ENG MIR21 PTEN TP53
3	negative regulation of gene expression	GO:0010629	9.9	ENG MIR21 NME1 TERT
4	positive regulation of ERK1 and ERK2 cascade	GO:0070374	9.89	CD44 EGFR MIR21 PTEN
5	response to drug	GO:0042493	9.83	CCND1 ENG NME1 PTEN XRCC1
6	negative regulation of apoptotic process	GO:0043066	9.8	CD44 EGFR GSTP1 MIR21 PTEN TERT
7	response to organic substance	GO:0010033	9.78	CCND1 PTEN XRCC1
8	positive regulation of protein phosphorylation	GO:0001934	9.78	CCND1 EGFR ENG MIR21
9	negative regulation of ERK1 and ERK2 cascade	GO:0070373	9.76	GSTP1 MIR21 PTEN
10	regulation of protein stability	GO:0031647	9.75	CDKN2A PTEN TERT
11	cellular response to drug	GO:0035690	9.73	EGFR NME1 TP53
12	response to estradiol	GO:0032355	9.62	CCND1 EGFR GSTP1 PTEN
13	positive regulation of superoxide anion generation	GO:0032930	9.61	EGFR GSTP1
14	positive regulation of production of miRNAs involved in gene silencing by miRNA	GO:1903800	9.57	EGFR TP53
15	mitotic G1 DNA damage checkpoint	GO:0031571	9.54	CCND1 TP53
16	positive regulation of vascular smooth muscle cell differentiation	GO:1905065	9.52	ENG MIR21
17	xenobiotic catabolic process	GO:0042178	9.49	GSTM1 GSTM3
18	nitrobenzene metabolic process	GO:0018916	9.46	GSTM1 GSTM3
19	cellular detoxification of nitrogen compound	GO:0070458	9.4	GSTM1 GSTM3
20	response to UV-A	GO:0070141	9.37	CCND1 EGFR
21	replicative senescence	GO:0090399	9.33	CDKN2A TERT TP53
22	glutathione metabolic process	GO:0006749	9.26	GSTM1 GSTM3 GSTP1 GSTT1
23	glutathione derivative biosynthetic process	GO:1901687	8.92	GSTM1 GSTM3 GSTP1 GSTT1

Molecular functions related to Larynx Cancer according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	identical protein binding	GO:0042802	9.87	EGFR ENG GSTM3 NME1 PTEN TERT
2	protein kinase binding	GO:0019901	9.73	CCND1 CDKN2A EGFR GSTP1 PTEN TP53
3	glutathione binding	GO:0043295	9.33	GSTM1 GSTM3 GSTP1
4	glutathione transferase activity	GO:0004364	9.26	GSTM1 GSTM3 GSTP1 GSTT1
5	enzyme binding	GO:0019899	9.23	CCND1 EGFR GSTM1 GSTM3 NME1 PTEN

Sources

Sources for Larynx Cancer

¹ BioSystems

² BitterDB

³ CDC

⁴ Cell Signaling Technology

⁵ ClinicalTrials

⁶ ClinVar

⁷ CNVD

⁸ Cochrane Library

⁹ Cosmic

¹⁰ dbSNP

¹¹ DGIdb

¹² Disease Ontology

¹³ diseasecard

¹⁴ DiseaseEnhancer

¹⁵ DISEASES

¹⁶ DrugBank

¹⁷ EFO

¹⁸ ExPASy

¹⁹ FDA Approved Drugs

²⁰ FMA

²¹ GeneAnalytics

²² GeneCards

²³ GeneGo (Thomson Reuters)

²⁴ GeneHancer via GeneCards

²⁵ GeneReviews

²⁶ Genetics Home Reference

²⁷ GenomeRNAi

²⁸ GEO DataSets

²⁹ GO

³⁰ GTR

³¹ HGMD

³² HMDB

³³ HPO

³⁴ ICD10

³⁵ ICD10 via Orphanet

³⁶ ICD9CM

³⁷ IUPHAR

³⁸ KEGG

³⁹ LifeMap

⁴⁰ LncRNADisease

⁴¹ LOVD

⁴² MalaCards

⁴³ MedGen

⁴⁴ MedlinePlus

⁴⁵ MeSH

⁴⁶ MESH via Orphanet

⁴⁷ MGI

⁴⁸ miR2Disease

⁴⁹ NCBI Bookshelf

⁵⁰ NCI

⁵¹ NCIt

⁵² NDF-RT

⁵³ NIH Clinical Center

⁵⁴ NIH Rare Diseases

⁵⁵ NINDS

⁵⁶ Novoseek

⁵⁷ Novus Biologicals

⁵⁸ OMIM

⁵⁹ OMIM via Orphanet

⁶⁰ Orphanet

⁶¹ PathCards

⁶² PharmGKB

⁶³ PubMed

⁶⁴ PubMed Health

⁶⁵ QIAGEN

⁶⁶ R&D Systems

⁶⁷ Reactome

⁶⁸ Sino Biological

⁶⁹ SNOMED-CT

⁷⁰ SNOMED-CT via HPO

⁷¹ SNOMED-CT via Orphanet

⁷² TGDB

⁷³ Tocris

⁷⁴ UMLS

⁷⁵ UMLS via Orphanet

⁷⁶ UniProtKB/Swiss-Prot

⁷⁷ Wikipedia